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Abstract
Background and aims: Few data are currently available for Kawasaki disease (KD) below 12 months especially in
Caucasians. This study aims to analyze clinical and laboratory features of KD among an Italian cohort of infants.
Methods: A retrospective chart review of KD children aged less than 1 year at time of disease onset between
January 2008–December 2017 was performed. Clinical data, laboratory parameters, instrumental findings, treatment
and outcome were collected in a customized database.
Results: Among 113 KD patients, 32 (28.3%) were younger than 1 year. Nineteen patients aged below 6months,
and three below 3 months. The median age was 5.7 ± 2.7 months. The mean time to diagnosis was 7 ± 3 days and
was longer in the incomplete forms (8 ± 4 vs 6 ± 1 days). Conjunctival injection was present in 26 patients (81.2%);
rash in 25 (78.1%); extremity changes in 18 (56.2%); mucosal changes in 13 (40.6%,) and lymphadenopathy only in 7
(21.8%). Mucosal changes were the least common features in incomplete forms (18.2%). Twenty-two patients
(68.7%) had incomplete KD. Nineteen (59.4%) had cardiac involvement, of whom 13 (59.0%) had incomplete form.
ESR, PCR and platelet values were higher in complete KD; especially, ESR resulted significantly higher in complete
forms (80 ± 25.7 mm/h vs 50 ± 28.6 mm/h; p = 0.01). Conversely, AST level was statistically significant higher in
patients with incomplete forms (95.4 ± 132.7 UI/L vs 29.8 ± 13.2 UI/L; p = 0.03). All patients received IVIG. Response
was reported in 26/32 patients; 6 cases needed a second dose of IVIG and one required a dose of anakinra.
Conclusion: In our cohort, incomplete disease was commonly found, resulting in delayed diagnoses and poor
cardiac prognosis. Infants with incomplete KD seem to have a more severe disease and a greater predilection for
coronary involvement than those with complete KD. AST was significantly higher in incomplete forms, thus AST
levels might be a new finding in incomplete forms’ diagnosis. Eventually, we highlight a higher resistance to IVIG
treatment. To our knowledge this is the first study involving an Italian cohort of patients with KD below 12 months.
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Background
Kawasaki disease (KD) is an acute medium vessel vascu-
litis of childhood, typically involving coronary arteries
[1–3]. It is one of the most common pediatric vasculitis
and the commonest cause of acquired heart disease in
children in developed countries. Current annual inci-
dence rates of KD in Japan, Korea and Taiwan are 264.8,
134.4 and 69 cases per 100,000 children below 5 years,
respectively [4–6]. The incidence rate in Italy is about
5.7 per 100,000 children 0–14 years old, and 14.7 for
children younger than 5 years [7]. It is seldom reported
below 3months of age: only 1.6% of all KD patients [8].
Current literature reports that infants below 12months
of age have a higher prevalence of incomplete and atyp-
ical KD (40%) compared to older patients (10–12%) [1].
Delayed diagnosis and treatment, higher incidence of
coronary arteries abnormalities, and greater intravenous
immunoglobulin (IVIG) resistance frequently occur in
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KD infants [9–16]. There is paucity of literature exclu-
sively on KD below the age of 12 months and little infor-
mation is available on this aspect of KD from any
developed country [16]. To the best of our knowledge
there are no published data on KD in infancy from other
Italian centers. We report the clinical data, laboratory
profile, instrumental findings and management of 32
children with KD, aged below 12 months who were
admitted to our institution in the last 10 years. Further-
more, within such cohort we compared babies with
complete KD to those with incomplete form, in order to
identify any clinical or laboratory data, potentially useful
in early detecting the incomplete forms. Moreover,
babies with coronary involvement were compared with
those without cardiac impairment, in an effort to detect
any clinical or hematological feature, which could
predict cardiac involvement.
Methods
This is a retrospective chart review of children diagnosed
with KD (ICD-9 discharge code 4461) between January
1st, 2008 and December 31st, 2017. KD children youn-
ger than 12months of age at disease onset were selected
and included in the analysis. Demographic (age, gender)
and clinical data, including season of onset, time to diag-
nosis, signs and symptoms, cardiac involvement, treat-
ment and outcome were collected. Delayed diagnosis
was defined as a KD diagnosis made after day 10 of
illness – the cut-off period generally considered most
appropriate for administration of IVIG. Complete and
incomplete KD were defined according to the American
Heart Association definition [3]. Echocardiograms were
performed at diagnosis, 2 weeks after disease onset and
after 6–8 weeks in all patients. Additionally, patients
with coronary artery abnormalities received echocardio-
grams depending on severity of illness as part of
standard of care. Patients were classified as having nor-
mal (< 2.5 SD units [z score] from the mean, normalized
for body surface area), dilated (z score ≥ 2.5 to < 4), or
aneurysmal (z ≥ 4; z > 10 for giant aneurysm) coronary
arteries on the base of the maximal internal diameters of
the right coronary artery and left anterior descending
artery [16]. With cardiac involvement was meant any
cardiac abnormalities (such as coronary involvement
and/or pericardial effusion and/or valvular regurgitation
and/or cardiac tamponade and/or arrhythmia). At first,
patients were divided in those who presented cardiac in-
volvement and those who did not. Moreover, in light of
coronary impairment, children with cardiac involvement
were subdivided in two groups: those with coronary
artery abnormalities (CAA) and those without. Lastly,
our cohort has been dividend in two further groups:
children below and over 6 months of age. Time to
diagnosis, cardiac involvement and CAA have been com-
pared between the two groups.
Furthermore, complete blood count, erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), sodium and albumin prior to IVIG treatment
were also collected. Laboratory tests have been per-
formed by standard methods in our clinical laboratory.
The range or the minimal value of laboratory tests (i.e.,
ESR ≤ 20 mm/hour, CRP ≤0.29 mg/dL, ALT ≤50 UI/L,
AST ≤ 35 UI/L, albumin 3,5–5 g/dl and sodium 125–135
mEq/L), detected by the standard assays, were used as
appropriate.
The response to IVIG was defined as IVIG-resistance
when persistent or recrudescent fever occurred between
36 h to 7 days after completion of the first IVIG infusion.
Categorical data were statistically analyzed by chi-square
analysis. Continuous data were analyzed by Student t test.
Adjustments were made for unequal variances using Sat-
terthwaite’s approximation. P values less than 0.05 were
considered statistically significant. All data were analyzed
by Epi Info Statistical Software version 7.1.5.2.
According to our local regulations, ethical approval
was not due for retrospective charts review.
Results
All the demographic and clinical data are shown in
Table 1, while the laboratory results are shown in Table 2.
Demographic profile
Between January 1, 2008 and December 31, 2017, 113
children have been diagnosed with KD in our hospital.
Among these, 32 infants aged below 1 year at time of
disease onset (28.3%) were included in the study. Nine-
teen patients were less than 6months, representing
59.3% of the selected population and 16.8% of all the KD
patients; 3 infants were below 3months of age (9.4% of
patients below 1 year of age and 2.6% of all patients di-
agnosed with KD). The youngest was a 30-day old male
infant. Mean age of presentation was 5.7 ± 2.7 months.
Most patients were males (M: F = 1.7:1). In terms of
season of onset, 12 patients (32.5%) developed KD in
December–February and 10 (31.2%) in June–August; 5/
32 (15.6%) in September–November and 5/32 (15.6%) in
March–May.
Clinical features
The mean time to diagnosis from the onset (day 1 of
fever) was 7 ± 3 days (range 3–22) and was longer in the
incomplete forms (8 ± 4 vs 6 ± 1 days). In 3 patients the
diagnosis of KD was made after day 10 of illness and
two developed cardiac involvement (coronary aneurism
and pericardial effusion respectively). In one of these
cases, the diagnosis was even delayed till day 22 and the
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boy developed coronary arteries aneurisms, pericardial
effusion and cardiac tamponade. Focusing on children
below 6months of age, they appeared to get a more
delayed diagnosis than the older infants (7 vs 6 days),
with no significant difference (p = 0.53). Conjunctival
injection was present in 26 patients (81.2%); rash in 25
(78.1%); extremity changes in 18 (56.2%); mucosal
changes in 13 (40.6%) and cervical lymphadenopathy in
7 (21.8%). Most patients (68.7%, 22 cases) had incom-
plete KD, in particular 7 fulfilled 3 criteria, 11 fulfilled 2
criteria and 4 fulfilled 1 criterion. With regard to cardiac
involvement, it was present in about 60% in both groups.
Furthermore, analyzing coronary involvement, CAA
were detected in 16/32 (50%) patients, 12 of whom had
an incomplete form (54.5%). Neither giant aneurisms
nor arrhythmia was found. Eight (25%) patients devel-
oped a pericardial effusion. No valvular regurgitation
was detected. Children below 6months of age showed a
slight greater predilection for cardiac involvement
(63.2%) and coronary disease (57.9%) than older infants
(53.8 and 30.8%, respectively) but without significant
difference (p = 0.59 and 0.28, respectively).
Laboratory data
Mean platelet count was 525.9 ± 192 103/microL and 7/32
(21.8%) had a normal platelet count at onset. One patient
developed thrombocytopenia (140 103/microL) and one
had a platelet count above 1000 103/microL (1012 103/
microL). In terms of developing CAA, no statistically sig-
nificant difference was found related to platelets count.
Mean total leukocyte count was 16.9 ± 8.5 103/microL.
Twenty-three of 32 patients had a leukocyte count above
12.0 103/microL. Sixteen of 23 (69.5%) had incomplete KD.
Mean hemoglobin level was 10.6 ± 1.3 g/dL. Six pa-
tients presented with a hemoglobin level < 10 mg/dl and
5 of them developed CAA. The median initial ESR was
elevated (mean 60 ± 30mm/h) in all patients. However,
mean ESR level in the complete forms was significantly
higher than in incomplete ones (80 ± 25.7 mm/h vs 50 ±
28.6 mm/h; p = 0.01). There was no significant difference
in ESR level when comparing CAA+ and CAA- groups.
CRP was evaluated in all patients: 31 of them had
raised levels, with a mean of 8.2 ± 6.8 mg/dL. Mean value
in complete forms (9.7 ± 9.6 mg/dL) is higher than in in-
complete ones (7.5 ± 5mg/dL) although without any sig-
nificant difference. The initial CRP level was high in a
comparable percentage of those who had CAA (8.6 ± 7.3
mg/dL) and those who did not (7.7 ± 6 mg/dL).
ALT and AST mean levels were 65 ± 72.3 U/L and
74.9 ± 113.7 U/L, respectively. Focusing on AST level, it
resulted much higher in incomplete forms than in
complete ones (95.4 ± 132.7 UI/L vs 29.8 ± 13.2 UI/L),
Table 1 Demographic and clinical data of children with Kawasaki disease below the age of 12 months
Clinical features Total Complete KD (n = 10) Incomplete KD (n = 22)
Mean age at onset 5.7 ± 2.8 months 7.4 ± 2.2 months 5.0 ± 2.8 months
Male: female ratio 20:12 4:6 16:6
Mean time to diagnosis 7 ± 3 days 6 ± 1 days 8 ± 4 days
Fever > 5 days 32/32 (100%) 10/10 (100%) 22/22 (100%)
Conjunctival injection 26/32 (81.2%) 10/10 (100%) 16/22 (72.7%)
Rash 25/32 (78.1%) 10/10 (100%) 15/22 (68.2%)
Extremity changes 18/32 (56.2%) 10/10 (100%) 8/22 (36.4%)
Mucosal changes 13/32 (40.6%) 9/10 (90%) 4/22 (18.2%)
Cervical lymphadenopathy 7/32 (21.9%) 2/10 (20%) 5/22 (22.7%)
Cardiac involvement 19/32 (59.4%) 6/10 (60%) 13/22 (59%)
Coronary abnormalities 16/32 (50%) 4/10 (40%) 12/22 (54.5%)
Table 2 Laboratory features of children with Kawasaki disease below the age of 12 months
Laboratory data at onset Total Complete KD Incomplete KD CAA- CAA+
Mean ± SD Platelet count 103/microL 525.9 ± 192.0 528.1 ± 137.3 524.9 ± 215.3 570.0 ± 216.8 495.7 ± 172.7
Mean ± SD Leukocyte count 103/microL 16.9 ± 8.5 18.1 ± 9.2 16.4 ± 8.3 16.3 ± 8.6 17.4 ± 8.6
Mean ± SD Hemoglobin 10.6 ± 1.3 10.7 ± 1.8 10.5 ± 1.0 10.9 ± 1.1 10.4 ± 1.5
Mean ± SD ESR mm/h 60.0 ± 30.6 80.1 ± 25.7* 50.5 ± 28.6* 62.5 ± 31.4 58.1 ± 30.9
Mean ± SD CRP mg/dl 8.2 ± 6.8 9.7 ± 9.6 7.5 ± 5.0 7.7 ± 6.0 8.6 ± 7.3
Mean ± SD ALT UI/L 65.0 ± 72.3 57.6 ± 56.3 68.4 ± 79.4 56.9 ± 79.6 70.5 ± 68.5
Mean ± SD AST UI/L 74.8 ± 113.7 29.8 ± 13.2* 95.4 ± 132.7* 59.8 ± 74.5 85.2 ± 135.2
*p < 0.05
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with a statistically significant difference (p = 0.03) be-
tween the two groups. On the other hand, no significant
difference in transaminases level was found in patients
with or without cardiac involvement.
Among the 28 patients in whom albumin levels were
evaluated, 19 developed hypoalbuminemia and 15/19
(78.9%) had an incomplete form. Furthermore, 12/19
(63.1%) developed heart involvement. Six patients pre-
sented hyponatremia; 4 of them had an incomplete form.
Three patients with hyponatremia developed CAA.
Treatment
All 32 patients received standard IVIG dose (2 g/kg in
single infusion) and high dose acetylsalicylic acid (ASA)
at 50 mg/kg/day orally in 4 divided doses, except for 7
patients with hypertransaminasemia (AST and /or ALT
> 2 DS) who skipped high dose ASA therapy for its po-
tential hepatotoxicity. After children have been afebrile
for 48 to 72 h, low antithrombotic ASA was always
administered, irrespective of transaminase levels. Six
children (19%), of whom 4 below 6months, needed a
second dose of IVIG and all of them presented CAA.
One child required a third dose of IVIG and then
additional treatment with anakinra (2 mg/kg). All pa-
tients healed from heart involvement except for 2, both
below 6months of age. Most of them recovered within
1 year, in two cases cardiac normalization was obtained
within 5 years with no long-term sequelae.
Discussion
There is paucity of data on the clinical presentation of
KD in infancy and none from Italy, so far. KD below 1
year of age can be very challenging to diagnose because
of unusual clinical presentations with a majority of in-
complete forms and paucity of clinical signs [10, 17, 18].
It is well known that infants with KD are more likely to
have cardiac involvement than older children [1–3, 10,
17, 18]. Whether the increased rate of coronary compli-
cations is exclusively due to the delayed diagnoses, and
consequently to a delayed treatment, is still unclear.
Among all our patients with KD the percentage of
infants, aged below 1 year (28.3%), was higher than
reported in a previous study (17.5%) [17]. Considering
patients younger than 6months, they were 19 (16.8%)
much more than reported by Park et al. (7.7%) [19] and
by Singh et al. (3.6%) [9]. Eventually, our percentage of
infants under 3-month-old (2.6%) was higher than 1.6%
reported in previous studies [8, 20].
In our cohort the mean time to diagnosis was 7 days,
and it was comprehensibly longer for incomplete forms.
In 3 patients the diagnosis of KD was made after day 10 of
illness and in one of them it was even delayed till day 22.
This boy developed coronary arteries aneurisms, pericar-
dial effusion and cardiac tamponade. Children below 6
months are reported to receive more often a late diagnosis
[12]. Therefore, time to diagnosis was compared in
patients aged below and over 6 months and the diagnosis
resulted slightly delayed in the youngest (7 vs 6 days).
Accordingly, the 3 patients diagnosed beyond 10 days,
were under 6months of age. Thus, pediatricians need to
have a high index of suspicion of KD evaluating infants,
especially under 6months, with unexplained fever for
more than 5 days, especially if unresponsive to antibiotics.
As reported in literature, in our cohort the most com-
mon clinical features were conjunctival injection, rash,
and extremity changes [1]. In contrast, in our cases mu-
cosal changes were found only in 40.6%, and lymphaden-
opathy was detected in 21.9%. The latter finding agrees
with two previous studies, reporting lymphadenopathy
in 17 and 5.7% of KD infants younger than 6months, re-
spectively [9, 16]. Indeed, lymphadenopathy is already
known as the least common of all manifestations in-
cluded in classical criteria. Rather, mucosal changes that
are described in literature as a usual sign, ranging from
64 to 96.5% [9, 21], were uncommonly found in our
cohort. In particular, in our infants with incomplete KD,
mucosal changes resulted to be the least common
clinical feature (18.2%).
In previously reported series, incomplete KD repre-
sents 15–20% of cases, being more frequent in children
below 12months of age [1, 4]. In our cohort the majority
of patients had incomplete KD (68.7%), which results
much more common than reported by Singh et al., who
found incomplete form in 35% of infants below 6
months, and in 12% of the overall KD patients [9].
Infants with KD are likely to have a more severe disease
and higher risk of cardiac involvement. In our cohort car-
diac involvement was present in about 60% in both
complete and incomplete groups, and CAA were detected
in 50% of patients, most of them had an incomplete form.
Both total cardiac involvement (60%) and CAA (50%) re-
sulted higher among our patients than previously reported
(40 and 25%, respectively) [3]. Shulman et al. described 36
KD patients, who were less than l year of age during the
pre-IVIG era and found that CAA developed in 31% com-
pared with 18% in those who were 1 to 2 years of age and
10% who were more than 2 years of age [22]. Also, in the
pre-IVIG era, Burns et al. reported that CAA developed in
6 out of 8 patients with KD aging less than 6months of
age [11], and Takahashi et al. reported a higher prevalence
of CAA in children less than 1 year of age (39%) than in
older children (13%) [23].
Cardiac involvement rate was 63.2% in children < 6
months (vs 59.4% in the older), with a higher rate of
CAA (57.9% vs 50.0%), but without statistically signifi-
cant difference.
As suggested in previous studies [9, 12], these findings
observe that in early infancy KD is associated with an
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increased proportion of cardiac involvement. Delayed
diagnosis and consequent delayed treatment could be
responsible for the higher rate of cardiac complications.
However, it is still an ongoing debate whether the
higher risk of developing CAA is solely due to the de-
layed diagnosis in incomplete forms or other factors
might be involved. Conversely to the literature findings
[24, 25], none of our patients developed arrhythmia or
valvular insufficiency.
As already observed [10], in our patients’ laboratory
findings were nonspecific neither diagnostic, and gener-
ally did not predict CAA development. Although most
of our patients had high platelets level, thrombocytosis
was not related to a higher risk of CAA development.
Only one patient had thrombocytopenia and he devel-
oped CAA. Indeed, thrombocytopenia is already known
as risk factor for cardiac involvement in KD [26].
In our serie, moderate up to marked leukocytosis was
found in 2/3 of our patients. Nevertheless, in those with
normal white blood cells count, cardiac involvement was
equally present, confirming that lack of leukocytosis did
not predict an uncomplicated course of illness.
ESR and CRP values were all higher in complete KD
forms than in incomplete ones; among these parameters
ESR value was significantly higher in the complete forms.
This result confirms that incomplete KD, with relatively
low inflammation markers, is ambiguous not only in terms
of clinical features, but also of laboratory findings, leading
to a delayed diagnosis. Furthermore, ESR, CRP and plate-
let levels were high in a comparable percentage of those
with CAA and those without, thus they are not predictive
of coronary disease, as already seen [10].
To date, AST level has not been reported to be signifi-
cantly higher in incomplete forms. We gathered from our
cohort a much higher AST level in incomplete forms than
in complete ones, with a statistically significant difference
between the two groups. This finding is quite impressive,
considering that no statistically significant laboratory data
has been found before to characterize incomplete KD.
More studies are needed to confirm whether AST level
might be included in KD criteria to detect incomplete
forms, but in real-life practice a high AST level might be
very useful when facing young infants with unexplained
fever lasting more than 5 days, who no fulfilled KD
criteria, whenever clinicians must weigh the trade-offs be-
tween a prompt IVIG therapy and the risk of missing
other diagnosis.
In contrast to this finding, no significant AST level
difference has been found between patients with or
without cardiac involvement. Thus, AST level cannot
be considered a possible biomarker of cardiac damage
in KD, despite the recognition of hepatic involvement
in association with other forms of myocarditis has
already been described [27].
Moreover, although not statistically significant, low
albumin levels were reported in higher percentage of pa-
tients with incomplete KD, as additional potential sign
of liver involvement in this KD form. Liver impairment
might be helpful as additional clue in the challenging
diagnosis of infants with incomplete KD.
A further aid for this difficult diagnosis could come
from genetic assessment. Recently, evidence for a genetic
component for KD susceptibility has been described [3].
Variants in the transforming growth factor (TGF)-β
signaling pathway (TGFβ2, TGFβR2, and SMAD3) genes
were associated with increased risk of aneurysm forma-
tion in Caucasian patients. Further works in this area
could be helpful to detect children at high risk of cardiac
involvement especially below 1 year of age.
In our cohort all patients received IVIG treatment. Six
children, all of them with CAA, required a second dose of
IVIG 24 h thereafter: four of them were below 6months.
One child (4-month-old) presenting with incomplete form
had resistant KD and required a third dose of IVIG and
then additional treatment with anakinra (2mg/kg). Indeed,
according to earlier studies [19, 28], age below 6-month
has been reported to be an important variable in predicting
IVIG resistance. The percentage of IVIG resistance among
our cohort of children was 19%, higher than reported by
Egami et al. (15%) describing patients of the same age [29].
This discrepancy was even more glaring when compared
to the overall IVIG resistance (10%) [29, 30]. To conclude,
our results highlight a higher resistance to treatment not
only in children below 6months of age as previously re-
ported [19, 28], but also in the ones below 1 year of age.
There is no consensus regarding optimal adjunctive
therapeutics for KD refractory to intravenous immuno-
globulins. Patients at high risk of coronary artery aneu-
rysms development may benefit from adjunctive therapy.
Our 4-month-old boy has been successfully treated with
anakinra. Our choice was based on some evidence that
anakinra, used late in the disease course, leads to a rapid
and sustained improvement in clinical and biological in-
flammation [31]. Indeed, recently the importance of IL-1
signaling pathway has been highlighted in patients with
KD [32–34].
Furthermore, we decided not to treat patients who pre-
sented hypertransaminasemia with high ASA doses to
avoid a potential hepatotoxicity. This choice did not affect
the cardiac outcome in our cohort as already stated by
literature. In fact, although ASA has important anti-in-
flammatory activity (at high doses) and antiplatelet activity
(at low doses), it does not appear to lower the frequency
of development of coronary abnormalities [35, 36].
However, the sample size limitation would be advocated.
Since our cohort encompasses only 32 patients, the in-
creased likelihood of a Type II error, skewing the results
and decreasing the power of the study, could be occur.
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Conclusions
In conclusion, KD clinical diagnosis below 1 year of age,
and even more below 6months, can be very challenging
since patients may not have classic signs and symptoms,
and individual manifestations may be subtle. Therefore,
in young infants with unexplained fever lasting more
than 5 days, a clinical possibility of KD must be consid-
ered and appropriate investigations performed. In this
clinical setting, liver function test evaluation might drive
the diagnosis. In fact, timely diagnosis and institution of
treatment with IVIG and aspirin is required to minimize
cardiac sequelae and long-term morbidity. To our know-
ledge this is the first study involving an Italian cohort of
patients with KD below 12 months. Further studies are
needed to define specific diagnostic criteria for this
particular group of age, even if the final diagnosis in
doubtful cases still relies on expert opinion.
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